Tags

Type your tag names separated by a space and hit enter

Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.
Endocr Pract 2011 Jan-Feb; 17(1):16-25EP

Abstract

OBJECTIVE

To investigate the effects of daily chromium picolinate supplementation on serum measures of glucose tolerance and insulin sensitivity in patients at high risk for type 2 diabetes mellitus.

METHODS

We conducted a randomized, double-blind, placebo-controlled, modified cross-over clinical trial with 6-month sequences of intervention and placebo followed by a 6-month postintervention assessment. Adult patients with impaired fasting glucose, impaired glucose tolerance, or metabolic syndrome were enrolled. Participants received 6-month sequences of chromium picolinate or placebo at 1 of 2 dosages (500 or 1000 mcg daily). Primary outcome measures were change in fasting plasma glucose, 2-hour plasma glucose during oral glucose tolerance testing, fasting and 2-hour insulin, and homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes included anthropometric measures, blood pressure, endothelial function, hemoglobin A1c, lipids, and urinary microalbumin.

RESULTS

Fifty-nine participants were enrolled. No changes were seen in glucose level, insulin level, or HOMA-IR (all P>.05) after 6 months of chromium at either dosage level (500 mcg or 1000 mcg daily) when compared with placebo. None of the secondary outcomes improved with either chromium dosage compared with placebo (P>.05).

CONCLUSIONS

Chromium supplementation does not appear to ameliorate insulin resistance or impaired glucose metabolism in patients at risk for type 2 diabetes and thus is unlikely to attenuate diabetes risk.

Authors+Show Affiliations

Prevention Research Center, Yale University School of Medicine, Derby, Connecticut 06418, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

20634174

Citation

Ali, Ather, et al. "Chromium Effects On Glucose Tolerance and Insulin Sensitivity in Persons at Risk for Diabetes Mellitus." Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, vol. 17, no. 1, 2011, pp. 16-25.
Ali A, Ma Y, Reynolds J, et al. Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocr Pract. 2011;17(1):16-25.
Ali, A., Ma, Y., Reynolds, J., Wise, J. P., Inzucchi, S. E., & Katz, D. L. (2011). Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 17(1), pp. 16-25. doi:10.4158/EP10131.OR.
Ali A, et al. Chromium Effects On Glucose Tolerance and Insulin Sensitivity in Persons at Risk for Diabetes Mellitus. Endocr Pract. 2011;17(1):16-25. PubMed PMID: 20634174.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. AU - Ali,Ather, AU - Ma,Yingying, AU - Reynolds,Jesse, AU - Wise,John Pierce,Sr AU - Inzucchi,Silvio E, AU - Katz,David L, PY - 2010/7/17/entrez PY - 2010/7/17/pubmed PY - 2011/8/2/medline SP - 16 EP - 25 JF - Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists JO - Endocr Pract VL - 17 IS - 1 N2 - OBJECTIVE: To investigate the effects of daily chromium picolinate supplementation on serum measures of glucose tolerance and insulin sensitivity in patients at high risk for type 2 diabetes mellitus. METHODS: We conducted a randomized, double-blind, placebo-controlled, modified cross-over clinical trial with 6-month sequences of intervention and placebo followed by a 6-month postintervention assessment. Adult patients with impaired fasting glucose, impaired glucose tolerance, or metabolic syndrome were enrolled. Participants received 6-month sequences of chromium picolinate or placebo at 1 of 2 dosages (500 or 1000 mcg daily). Primary outcome measures were change in fasting plasma glucose, 2-hour plasma glucose during oral glucose tolerance testing, fasting and 2-hour insulin, and homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes included anthropometric measures, blood pressure, endothelial function, hemoglobin A1c, lipids, and urinary microalbumin. RESULTS: Fifty-nine participants were enrolled. No changes were seen in glucose level, insulin level, or HOMA-IR (all P>.05) after 6 months of chromium at either dosage level (500 mcg or 1000 mcg daily) when compared with placebo. None of the secondary outcomes improved with either chromium dosage compared with placebo (P>.05). CONCLUSIONS: Chromium supplementation does not appear to ameliorate insulin resistance or impaired glucose metabolism in patients at risk for type 2 diabetes and thus is unlikely to attenuate diabetes risk. SN - 1934-2403 UR - https://www.unboundmedicine.com/medline/citation/20634174/Chromium_effects_on_glucose_tolerance_and_insulin_sensitivity_in_persons_at_risk_for_diabetes_mellitus_ L2 - http://journals.aace.com/doi/10.4158/EP10131.OR?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -